Study S002010

A Single-centre, Open Labeled, Fixed-sequence Study to Evaluate the Effect of Supaglutide on Digoxin or Metformin Pharmacokinetics

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05694221
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 34
Start: 2023-03-20
Primary completion: 2023-06-06
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Healthy Volunteers
Interventions: DRUG:Supaglutide injection; DRUG:Digoxin; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Group A: Plasma Cmax of digoxin [39 Days]
Group A: Plasma AUC0-last of digoxin [39 Days]
Group A: Plasma AUC0-inf of digoxin [39 Days]
Group B: Plasma Cmax,ss of Metformin [34 Days]
Group B: Plasma AUC0-tau of Metformin [34 Days]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005035	Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants. Wu X, Clinical pharmacokinetics	2025	Other trial	PMID 40587051 DOI	cites ClinicalTrials.gov:NCT05694221; registry reference DERIVED:40587051